A Phase 2, Randomized, Placebo Controlled Study Investigating the Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus - Trial NCT06227221
Access comprehensive clinical trial information for NCT06227221 through Pure Global AI's free database. This Phase 2 trial is sponsored by Second Xiangya Hospital of Central South University and is currently Not yet recruiting. The study focuses on Type 1 Diabetes. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Second Xiangya Hospital of Central South University
Timeline & Enrollment
Phase 2
Jun 01, 2024
Dec 01, 2026
Primary Outcome
The primary endpoint of the study is the change from baseline of serum C-peptide area under the curve (AUC) over 2 hours following a mixed meal
Summary
The purpose of this study is to investigate the therapeutic effect and safety of Sorafenib in
 T1DM patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06227221
Non-Device Trial